Cure: FDA approves tablet form of blood cancer treatment
UC expert says more patients may potentially benefit from approval
Following positive results of clinical trials, the Food and Drug Administration recently approved a tablet version of a drug called Calquence for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and previously treated relapsed or refractory mantle cell lymphoma (MCL).
The drug was previously approved in capsule form, but the tablet form is able to be given to patients who are also taking drugs that reduce gastric acid.
"Patients with blood cancers like chronic lymphocytic leukemia and mantle cell lymphoma are often older and may face multiple medical conditions that may need intervention, including acid reflux or peptic ulcer disease,” John Byrd, MD, University of Cincinnati Cancer Center member, Gordon and Helen Hughes Taylor Endowed Chair and professor in the Department of Internal Medicine in UC's College of Medicine and a UC Health physician, told the publication Cure. “This provides another option for some patients with chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma, enabling more patients to potentially benefit from this treatment.”
Read the Cure article.
Featured photo of John Byrd, MD. Photo/University of Cincinnati.
Related Stories
Mural by UC grad honors U.S. military history
July 17, 2024
Local 12 highlighted a new mural by University of Cincinnati graduate and artist Brandon Hawkins that pays tribute to U.S. military history.
Social media fuels extreme political rhetoric
July 17, 2024
UC College of Arts and Sciences Professor Jeffrey Blevins tells Local 12 that online algorithms fuel political polarization on social media.
Camp aims to empower children, teens who stutter
July 17, 2024
A one-week, evidence-based program for children and teens who stutter at the University of Cincinnati will teach kids to communicate effectively, advocate for themselves and develop confidence about their communication abilities. Camp Dream. Speak. Live., which is coming to Cincinnati for the first time July 22-26, began in 2014 at the University of Texas at Austin. The Arthur M. Blank Center for Stuttering Education and Research at UT expects to serve more than 2,000 children at camps across the United States, Africa, Asia and Europe this year.